Comparison of prognostic factors and biochemical disease-free survival (BDFS) in men with prostate cancer younger than age 65, age 65 to 75, and age 75 or older treated with combined simultaneous radiotherapy.

e15029 Background: Recent reports have questioned the utility of screening and/or treating men 75 years of age or older with prostate cancers because of presumed indolent nature of these cancers, and efficacy of treatment in such population Methods: Between September 1992 and January 2006, we reviewed 4,209 consecutive patients who had clinical stage (T1, T2, N0, M0), hormonal naive prostate cancers treated with I-125 seed implants, followed by external beam image guided radiotherapy (combined simultaneous radiotherapy). These men were followed for a minimum of five years. The primary end points were biochemical disease free survival (BDFS), and evaluation of pre-treatment prognostic factors between age groups < 65, 65 to 74, and 75 or older. Results: Of the 4,209 eligible men, 2160, 1758, and 291 were in the < 65, 65 to 74, and 75 or older groups, respectively. Utilizing the National Comprehensive Cancer Network (NCCN) risk group stratification, the < 65 group contained 1291(60%), 527(24%), and 342(16%) ...